Biogen (BIIB) Says it Plans Regulatory Filing for Aducanumab in Alzheimer's Disease After Consulting with FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Biogen (BIIB) PT Raised to $305 at Canaccord Genuity
October 23, 2019 5:14 AM EDTCanaccord Genuity analyst Sumant Kulkarni raised the price target on Biogen (NASDAQ: BIIB) to $305.00 (from $285.00) while maintaining a Hold rating.
... MoreBiogen (BIIB) PT Raised to $297 at BMO Capital
October 23, 2019 4:44 AM EDTBMO Capital analyst George Farmer raised the price target on Biogen (NASDAQ: BIIB) to $297.00 (from $250.00) while maintaining a Market Perform rating.
The analyst comments "After a failed futility analysis reported last March, new results from the Phase 3 trials, EMERGE and ENGAGE, now support... More
Biogen (BIIB) PT Raised to $310 at Jefferies
October 22, 2019 1:45 PM EDTJefferies analyst Michael Yee raised the price target on Biogen (NASDAQ: BIIB) to $310.00 (from $255.00) while maintaining a Hold rating.
stock pricing in renewed hopes againasks if M&A could be next... MoreBiogen (BIIB) News 'Somewhat Astonishing', Shares Could Trade Back Toward Low-$300s - RBC
October 22, 2019 7:32 AM EDTRBC Capital analyst Brian Abrahams weighed in on news Biogen (NASDAQ: BIIB) will pursue regulatory approval of aducanumab in Alzheimer's.
"We expect more clarity on BIIB's earnings call this morning but believe that given the multi-$B potential opportunity, we could see shares initially... More
Biogen (BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimer’s Disease
October 22, 2019 6:41 AM EDTBiogen (NASDAQ: BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimers Disease
... More